title: Stem cell-based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study.
abstract: Distal tibial fractures tend towards delayed- or nonunion. The purpose of this study was to evaluate the safety and efficacy of early minimally invasive intervention (MII) in the treatment of these fractures. A total 24 consecutive patients who underwent operative treatment for distal tibial fractures were randomized into a control and an intervention group. MII entailed aspirating iliac crest bone marrow and peripheral blood, yielding mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) respectively, that were mixed with demineralized bone matrix (DBM) and injected under fluoroscopic control into the fracture site. No complications occurred in either group. The median time to union was 1.5 months in the MII group and 3 months in the control group. MII was found to be a safe and efficient procedure.
authors.affiliation: Department of Orthopedic Surgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. liebergall@hadassah.org.il
authors.forename: Meir
authors.initials: M
authors.lastname: Liebergall
authors.forename: Josh
authors.initials: J
authors.lastname: Schroeder
authors.forename: Rami
authors.initials: R
authors.lastname: Mosheiff
authors.forename: Zulma
authors.initials: Z
authors.lastname: Gazit
authors.forename: Zilberman
authors.initials: Z
authors.lastname: Yoram
authors.forename: Linda
authors.initials: L
authors.lastname: Rasooly
authors.forename: Anat
authors.initials: A
authors.lastname: Daskal
authors.forename: Amal
authors.initials: A
authors.lastname: Khoury
authors.forename: Yoram
authors.initials: Y
authors.lastname: Weil
authors.forename: Shaul
authors.initials: S
authors.lastname: Beyth
mesh_terms: D000293:Adolescent; D000328:Adult; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects; D005260:Female; D005599:Fractures, Ununited / Q000628:therapy*; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome; D055815:Young Adult